Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

• INO-4500 (Drug): INO-4500 will be administered ID on Day 0 and Week 4.
• Placebo (Drug), also known as SSC-0001: Placebo will be administered ID on Day 0 and Week 4.
• CELLECTRA® 2000 (Device): EP using the CELLECTRA® 2000 device will be administered following ID drug administration.

Primary outcomes

• Percentage of Participants with Adverse Events (AEs) [Baseline up to Week 48]
• Percentage of Participants with Injection Site Reactions [Day 0 up to Week 48]
• Incidence of adverse events of special interest [Baseline up to Week 48]

Secondary outcomes

• Change from Baseline in Antigen Specific Binding Antibody titers [Day 0 up to Week 48]
• Change from Baseline in Lassa virus (LASV) Neutralizing Antibodies [Day 0 up to Week 48]
• Change from Baseline in Interferon-Gamma Response Magnitude [Day 0 up to Week 48]

Sex: All, ages: 18 Years to 50 Years, accepts healthy volunteers

Inclusion Criteria:

* Judged to be healthy by the Investigator on the basis of medical history, physical examination and vital signs performed at Screening;
* Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human Immunodeficiency Virus (HIV) antibody;
* Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically significant findings (e.g. Wolff-Parkinson-White syndrome);
* Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until 6 months following last dose or be post-menopausal or be surgically sterile or have a partner who is sterile.

Exclusion Criteria:

* Pregnant or breastfeeding, or intending to become pregnant or father children within the projected duration of the trial starting with the screening visit until 1 month following last dose;
* Is currently participating in or has participated in a study with an investigational product within 30 days preceding Day 0;
* Previous receipt of an investigational vaccine product for prevention of Lassa Fever;
* Fewer than two acceptable sites available for ID injection and EP considering the deltoid and anterolateral quadriceps muscles;
* Audiometry testing that demonstrates a hearing level threshold of 30 dB or greater for any frequency tested between 250 Hz - 8000 Hz;
* Recent (within 6 months) or planned travel to Lassa-endemic region;
* Current or anticipated concomitant immunosuppressive therapy.

• Mammen Mammen, MD, FACP, FIDSA, Study director, Inovio Pharmaceuticals